"Ensures Both Safety and Convenience of Administration"

Daewon Pharmaceutical announced on June 15 that it has launched a new combination therapy for dyslipidemia, Uptava Extended-Release Tablets.


Uptava Extended-Release Tablets are a combination therapy for dyslipidemia, containing 2 mg of pitavastatin calcium and 178.8 mg of fenofibrate choline as the main ingredients. The new product has improved medication convenience and treatment persistence by converting the existing capsule formulation into an extended-release tablet form.


Daewon Pharmaceutical's new dyslipidemia treatment product, 'Uptava Extended-Release Tablets'. Daewon Pharmaceutical

Daewon Pharmaceutical's new dyslipidemia treatment product, 'Uptava Extended-Release Tablets'. Daewon Pharmaceutical

View original image

For Uptava Extended-Release Tablets, the main ingredient has been changed from the conventional granule form to fenofibrate choline, ensuring equivalent efficacy regardless of food intake. To enhance convenience, the tablet size has also been reduced to be the smallest among combination products with the same active ingredients currently available on the market.



A Daewon Pharmaceutical representative stated, “Uptava Extended-Release Tablets combine pitavastatin, which reduces the risk of adverse reactions associated with statin monotherapy, with fenofibrate, which is highly effective in controlling triglycerides. With the convenience of administration regardless of food intake and the significantly smaller tablet size, this product will provide a more useful treatment option for patients with combination-type dyslipidemia.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing